Company intelligence / Profile preview

Aatru Medical, LLC

Cleveland, Ohio, USAaatru.com ↗

Ownership: Private
Employees: ~49
Development stage: NDA

Overview

The NPSIMS system received FDA Class II clearance in August 2021. Clinical studies have demonstrated usability and human factors validation. Interim clinical results were presented at major wound care conferences, with the company winning first place for oral abstracts at SAWC Spring 2024. Commercial sales are ongoing in the US and Latin America.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Device-based therapy (Negative Pressure Wound Therapy - NPWT)
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

vibegron

NDA

Indications: Overactive bladder, Benign prostatic hyperplasia

1 more asset in the full pipeline.

Request access →

Partnerships

Distribution agreement(s) for Latin America noted; specific partners not named.

Beyond the preview

Go deeper on Aatru Medical, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aatru Medical, LLC.

Explore the full profile